Skip to main content
Search
Search
Advanced Search
Skip main navigation
Free access
Industry Update
6 January 2022

R WE ready for reimbursement? A round up of developments in real-world evidence relating to HTA: part 5

Authors: Alex Simpson and Sreeram V Ramagopalan [email protected]Author Info & Affiliations
Volume 11, Number 4
https://doi.org/10.2217/cer-2021-0302
PDFFormats

Abstract

In the latest update we focus on recent publications which have provided insights into the importance of focusing on the development and consideration of a body of real-world evidence, and an approach to evaluating the complex area of treatment sequencing.

Formats available

You can view the full content in the following formats:

View PDFView Full Text

References

1.
Hill AB. The environment and disease: association or causation? Proc. R. Soc. Med. 58(5), 295–300 (1965).
PubMed
Google Scholar
2.
Rivera DR, Henk HJ, Garrett-Mayer E et al. The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: methodological recommendations from oncology case studies. Clin. Pharmacol. Ther. 111(1), 283–292 (2022).
PubMed
Google Scholar
3.
Lasiter L, Tymejczyk O, Garrett-Mayer E et al. Real-world overall survival using oncology electronic health record data: Friends of Cancer Research Pilot. Clin. Pharmacol. Ther. (2021) (Epub ahead of print).
Crossref
Google Scholar
4.
Kent S, Burn E, Dawoud D et al. Common problems, common data model solutions: evidence generation for health technology assessment. Pharmacoeconomics 39(3), 275–285 (2021).
Crossref
PubMed
Google Scholar
5.
Piena MA, Schoeman O, Harty GT, Wong SL. Desirability and acceptability of a treatment-sequencing model in relapsing-remitting multiple sclerosis: a health technology assessment perspective. Int. J. Technol. Assess. Health Care 36(2), 162–166 (2020).
PubMed
Google Scholar
6.
Zheng Y, Pan F, Sorensen S. Modeling treatment sequences in pharmacoeconomic models. Pharmacoeconomics 35(1), 15–24 (2017).
PubMed
Google Scholar
7.
Simonsen CS, Flemmen HØ, Broch L et al. Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry. Front. Neurol. 12, 693017 (2021).
PubMed
Google Scholar
8.
Brown JWL, Coles A, Horakova D et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 321(2), 175–187 (2019).
PubMed
Google Scholar
9.
He A, Merkel B, Brown JWL et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 19(4), 307–316 (2020).
PubMed
Google Scholar
10.
Spelman T, Magyari M, Piehl F et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol. 78(10), 1197–1204 (2021).
PubMed
Google Scholar
11.
Vertosick EA, Assel M, Vickers AJ. A systematic review of instrumental variable analyses using geographic region as an instrument. Cancer Epidemiol. 51, 49–55 (2017).
PubMed
Google Scholar
|